{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:12:17Z","timestamp":1790694737460,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T00:00:00Z","timestamp":1554854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1038\/s41416-019-0435-4","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T19:07:30Z","timestamp":1554836850000},"page":"959-967","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial"],"prefix":"10.1038","volume":"120","author":[{"name":"on behalf of the SOLE Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Ribi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixiu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Colleoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquie","family":"Chirgwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Aebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Jerusalem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Lauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry L.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ruhstaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehtesham","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Biganzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelore","family":"Barbeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pascale","family":"Graas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Rabaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prudence A.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Foukakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Graiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vorobiof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Maibach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Di Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Gelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron","family":"Goldhirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith M.","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrg","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,10]]},"reference":[{"key":"435_CR1","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1158\/0008-5472.CAN-07-5999","volume":"68","author":"GJ Sabnis","year":"2008","unstructured":"Sabnis, G. J., Macedo, L. F., Goloubeva, O., Schayowitz, A., Brodie, A. M. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res. 68, 4518\u20134524 (2008).","journal-title":"Cancer Res."},{"key":"435_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1470-2045(17)30715-5","volume":"19","author":"M Colleoni","year":"2018","unstructured":"Colleoni, M., Luo, W., Karlsson, P., Chirgwin, J., Aebi, S., Jerusalem, G. et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 19, 127\u2013138 (2018).","journal-title":"Lancet Oncol."},{"key":"435_CR3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10549-006-9260-6","volume":"100","author":"D Cella","year":"2006","unstructured":"Cella, D., Fallowfield, L., Barker, P., Cuzick, J., Locker, G., Howell, A. et al. Quality of life of postmenopausal women in the ATAC (\"Arimidex\", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res. Treat. 100, 273\u2013284 (2006).","journal-title":"Breast Cancer Res. Treat."},{"key":"435_CR4","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/bjc.2012.43","volume":"106","author":"LJ Fallowfield","year":"2012","unstructured":"Fallowfield, L. J., Kilburn, L. S., Langridge, C., Snowdon, C. F., Bliss, J. M., Coombes, R. C. et al. Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. Br. J. Cancer 106, 1062\u20131067 (2012).","journal-title":"Br. J. Cancer"},{"key":"435_CR5","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa032312","volume":"349","author":"PE Goss","year":"2003","unstructured":"Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349, 1793\u20131802 (2003).","journal-title":"N. Engl. J. Med."},{"key":"435_CR6","doi-asserted-by":"publisher","first-page":"6931","DOI":"10.1200\/JCO.2005.11.181","volume":"23","author":"TJ Whelan","year":"2005","unstructured":"Whelan, T. J., Goss, P. E., Ingle, J. N., Pater, J. L., Tu, D., Pritchard, K. et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J. Clin. Oncol. 23, 6931\u20136940 (2005).","journal-title":"J. Clin. Oncol."},{"key":"435_CR7","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/jnci\/dji069","volume":"97","author":"AL Stanton","year":"2005","unstructured":"Stanton, A. L., Bernaards, C. A. & Ganz, P. A. The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer. J. Natl Cancer Inst. 97, 448\u2013456 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"435_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1200\/JCO.1998.16.2.501","volume":"16","author":"PA Ganz","year":"1998","unstructured":"Ganz, P. A., Rowland, J. H., Desmond, K., Meyerowitz, B. E. & Wyatt, G. E. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J. Clin. Oncol. 16, 501\u2013514 (1998).","journal-title":"J. Clin. Oncol."},{"key":"435_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10549-007-9682-9","volume":"109","author":"D Cella","year":"2008","unstructured":"Cella, D., Land, S. R., Chang, C. H., Day, R., Costantino, J. P., Wolmark, N. et al. Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women. Breast Cancer Res. Treat. 109, 515\u2013526 (2008).","journal-title":"Breast Cancer Res. Treat."},{"key":"435_CR10","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/pon.1806","volume":"20","author":"L Terhorst","year":"2011","unstructured":"Terhorst, L., Blair-Belansky, H., Moore, P. J. & Bender, C. Evaluation of the psychometric properties of the BCPT Symptom Checklist with a sample of breast cancer patients before and after adjuvant therapy. Psychooncology 20, 961\u2013968 (2011).","journal-title":"Psychooncology"},{"key":"435_CR11","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0140-6736(15)01169-1","volume":"387","author":"PA Ganz","year":"2016","unstructured":"Ganz, P. A., Cecchini, R. S., Julian, T. B., Margolese, R. G., Costantino, J. P., Vallow, L. A. et al. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387, 857\u2013865 (2016).","journal-title":"Lancet"},{"key":"435_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1023\/A:1008269715091","volume":"8","author":"J Bernhard","year":"1997","unstructured":"Bernhard, J., Hurny, C., Coates, A. S., Peterson, H. F., Castiglione-Gertsch, M., Gelber, R. D. et al. Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group. Ann. Oncol. 8, 825\u2013835 (1997).","journal-title":"Ann. Oncol."},{"key":"435_CR13","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S1470-2045(15)00049-2","volume":"16","author":"J Bernhard","year":"2015","unstructured":"Bernhard, J., Luo, W., Ribi, K., Colleoni, M., Burstein, H. J., Tondini, C. et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 16, 848\u2013858 (2015).","journal-title":"Lancet Oncol."},{"key":"435_CR14","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1200\/JCO.2015.64.8675","volume":"34","author":"K Ribi","year":"2016","unstructured":"Ribi, K., Luo, W., Bernhard, J., Francis, P. A., Burstein, H. J., Ciruelos, E. et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. J. Clin. Oncol. 34, 1601\u20131610 (2016).","journal-title":"J. Clin. Oncol."},{"key":"435_CR15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/oxfordjournals.annonc.a058027","volume":"2","author":"P Butow","year":"1991","unstructured":"Butow, P., Coates, A., Dunn, S., Bernhard, J. & Hurny, C. On the receiving end. IV: validation of quality of life indicators. Ann. Oncol. 2, 597\u2013603 (1991).","journal-title":"Ann. Oncol."},{"key":"435_CR16","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1054\/bjoc.2001.1785","volume":"84","author":"J Bernhard","year":"2001","unstructured":"Bernhard, J., Sullivan, M., Hurny, C., Coates, A. S. & Rudenstam, C. M. Clinical relevance of single item quality of life indicators in cancer clinical trials. Br. J. Cancer 84, 1156\u20131165 (2001).","journal-title":"Br. J. Cancer"},{"key":"435_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/00005650-199603000-00004","volume":"34","author":"C Hurny","year":"1996","unstructured":"Hurny, C., Bernhard, J., Coates, A., Peterson, H. F., Castiglione-Gertsch, M., Gelber, R. D. et al. Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. Med. Care. 34, 234\u2013248 (1996).","journal-title":"Med. Care."},{"key":"435_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/BF00366447","volume":"1","author":"C Hurny","year":"1993","unstructured":"Hurny, C., Bernhard, J., Bacchi, M., van Wegberg, B., Tomamichel, M., Spek, U. et al. The perceived adjustment to chronic illness scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG). Support Care Cancer 1, 200\u2013208 (1993).","journal-title":"Support Care Cancer"},{"key":"435_CR19","first-page":"65","volume":"20","author":"J Bernhard","year":"2002","unstructured":"Bernhard, J., Maibach, R., Thurlimann, B., Sessa, C. & Aapro, M. S., Swiss Group for Clinical Cancer R. Patients' estimation of overall treatment burden: why not ask the obvious? J. Clin. Oncol. 20, 65\u201372 (2002).","journal-title":"J. Clin. Oncol."},{"key":"435_CR20","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(96)90936-8","volume":"347","author":"C Hurny","year":"1996","unstructured":"Hurny, C., Bernhard, J., Coates, A. S., Castiglione-Gertsch, M., Peterson, H. F., Gelber, R. D. et al. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet 347, 1279\u20131284 (1996).","journal-title":"Lancet"},{"key":"435_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1200\/JCO.2005.04.5393","volume":"25","author":"J Bernhard","year":"2007","unstructured":"Bernhard, J., Zahrieh, D., Castiglione-Gertsch, M., Hurny, C., Gelber, R. D., Forbes, J. F. et al. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients\u2014the International Breast Cancer Study Group Trial VIII. J. Clin. Oncol. 25, 263\u2013270 (2007).","journal-title":"J. Clin. Oncol."},{"key":"435_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1081\/BIP-120028507","volume":"14","author":"JA Sloan","year":"2004","unstructured":"Sloan, J. A. & Dueck, A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J. Biopharm. Stat. 14, 73\u201396 (2004).","journal-title":"J. Biopharm. Stat."},{"key":"435_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1604700","volume":"375","author":"PE Goss","year":"2016","unstructured":"Goss, P. E., Ingle, J. N., Pritchard, K. I., Robert, N. J., Muss, H., Gralow, J. et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N. Engl. J. Med. 375, 209\u2013219 (2016).","journal-title":"N. Engl. J. Med."},{"key":"435_CR24","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","volume":"28","author":"G Curigliano","year":"2017","unstructured":"Curigliano, G., Burstein, H. J., PW, E., Gnant, M., Dubsky, P., Loibl, S. et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann. Oncol. 28, 1700\u20131712 (2017).","journal-title":"Ann. Oncol."},{"key":"435_CR25","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1200\/JCO.2017.75.7500","volume":"36","author":"J Lemieux","year":"2018","unstructured":"Lemieux, J., Brundage, M. D., Parulekar, W. R., Goss, P. E., Ingle, J. N., Pritchard, K. I. et al. Quality of Life from Canadian Cancer Trials Group MA.17R: a randomized trial of extending adjuvant letrozole to 10 years. J. Clin. Oncol. 36, 563\u2013571 (2018).","journal-title":"J. Clin. Oncol."},{"key":"435_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1023\/A:1015276414526","volume":"11","author":"D Cella","year":"2002","unstructured":"Cella, D., Hahn, E. A. & Dineen, K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual. Life Res. 11, 207\u2013221 (2002).","journal-title":"Qual. Life Res."}],"updated-by":[{"DOI":"10.1038\/s41416-019-0709-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000}}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0435-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0435-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0435-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:04:36Z","timestamp":1684602276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0435-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["435"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0435-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,10]]},"assertion":[{"value":"30 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2020","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Colleoni reports advisory board fees from AstraZeneca, Pierre Fabre, Pfizer, OBI Pharma, Puma Biotechnology, Celldex; and honoraria from Novartis. Dr Karlsson reports advisory board fees from Novartis. Dr Jerusalem reports grants from Novartis, Roche, Amgen, BMS, and MSD; personal fees from Novartis, Roche, Lilly, Celgene, Amgen, BMS, Pfizer, Puma, Daiichi-Sankyo, MSD, and AstraZeneca; and non-financial support from Novartis, Roche, Lilly, BMS, and AstraZeneca. Dr Ruhstaller reports travel grants from Roche and Amgen; and advisory board fees from Novartis, Roche, AstraZeneca, and Lilly; and honoraria from Pfizer. Dr Francis reports personal fees from AstraZeneca and Novartis; and non-financial support from Pfizer: Dr Foukakis reports an institutional grant from Pfizer; and personal fees from Novartis and UpToDate. Dr Leo reports grants from AstraZeneca, Pierre Fabre, and Pfizer; and personal fees from AstraZeneca, Bayer, Celgene, Daichii-Sankyo, Eisai, Genomic Health, Ipsen, Lilly, Novartis, Pierre Fabre, Pfizer, and Roche. Dr Gelber reports institution fees from Novartis, Pfizer, AstraZeneca, Merck, Celgene, Ferring, Roche, and Ipsen. Dr Goldhirsch reports that the institute received a per-patient fee from the IBCSG for trial conduct. Dr Regan reports grants from International Breast Cancer Study Group, during the conduct of the study; grants from Novartis, grants from Pfizer, grants from Ipsen, outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics committees and appropriate national health authorities from each centre approved the protocol, including this sub-study, and all patients provided written informed consent as part of the informed consent for the main trial. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The data on which these analyses are based forms part of the clinical trials database of the International Breast Cancer Study Group, and as such is available for use on application in accordance with IBCSG data sharing policy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}